[go: up one dir, main page]

MA42780A - Sels d'un inhibiteur de la kinase pim - Google Patents

Sels d'un inhibiteur de la kinase pim

Info

Publication number
MA42780A
MA42780A MA042780A MA42780A MA42780A MA 42780 A MA42780 A MA 42780A MA 042780 A MA042780 A MA 042780A MA 42780 A MA42780 A MA 42780A MA 42780 A MA42780 A MA 42780A
Authority
MA
Morocco
Prior art keywords
salts
pim inhibitor
kinase pim
kinase
inhibitor
Prior art date
Application number
MA042780A
Other languages
English (en)
Inventor
Ganfeng Cao
Zhongjiang Jia
Qun Li
Qiyan Lin
Yongchun Pan
Lei Qiao
Vaqar Sharief
Chongsheng Eric Shi
Michael Xia
Changsheng Zheng
Jiacheng Zhou
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of MA42780A publication Critical patent/MA42780A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Plant Substances (AREA)
MA042780A 2015-09-09 2016-09-09 Sels d'un inhibiteur de la kinase pim MA42780A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562216045P 2015-09-09 2015-09-09
US201562244933P 2015-10-22 2015-10-22

Publications (1)

Publication Number Publication Date
MA42780A true MA42780A (fr) 2018-07-18

Family

ID=56985689

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042780A MA42780A (fr) 2015-09-09 2016-09-09 Sels d'un inhibiteur de la kinase pim

Country Status (24)

Country Link
US (6) US9862705B2 (fr)
EP (1) EP3347351B1 (fr)
JP (1) JP6943844B2 (fr)
KR (1) KR102720267B1 (fr)
CN (2) CN114380798B (fr)
AR (1) AR105967A1 (fr)
AU (2) AU2016320892C1 (fr)
CA (1) CA2997768C (fr)
CL (3) CL2018000611A1 (fr)
CO (1) CO2018003739A2 (fr)
EA (1) EA201890663A1 (fr)
EC (1) ECSP18026386A (fr)
ES (1) ES2914686T3 (fr)
IL (2) IL257897B2 (fr)
MA (1) MA42780A (fr)
MX (2) MX388988B (fr)
MY (2) MY187993A (fr)
PE (1) PE20181337A1 (fr)
PH (1) PH12018500511A1 (fr)
SG (1) SG10201912287XA (fr)
TW (1) TWI734699B (fr)
UA (1) UA124877C2 (fr)
WO (1) WO2017044730A1 (fr)
ZA (1) ZA201802267B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2945939T (lt) 2013-01-15 2020-07-27 Incyte Holdings Corporation Triazolkarboksamidai ir piridinkarboksamido junginiai, naudotini kaip pim kinazės inhibitoriai
EP3036238A1 (fr) 2013-08-23 2016-06-29 Incyte Corporation Composés de furo- et thiéno-pyridinecarboxamide utiles en tant qu'inhibiteurs de kinases pim
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (fr) 2015-10-02 2017-04-06 Incyte Corporation Composés hétérocycliques utiles en tant qu'inhibiteurs de la kinase pim
TW201924683A (zh) * 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP3967307A1 (fr) 2020-09-15 2022-03-16 Instytut Hematologii I Transfuzologii Utilisation d'inhibiteurs de la pim kinase pour augmenter l'efficacité des thérapies anti-cd20 à base d'anticorps dans les malignités hématologiques et les affections non malignes

Family Cites Families (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1294358B1 (fr) 2000-06-28 2004-08-18 Smithkline Beecham Plc Procede de broyage par voie humide
AU2002246864A1 (en) 2000-12-27 2002-07-24 The Trustees Of Columbia University In The City Of New York Pim kinase-related methods
ES2365905T3 (es) * 2001-03-30 2011-10-13 King Pharmaceuticals, Inc. Compuestos de tiofeno condensados y uso de los mismos en el tratamiento del dolor crónico.
DE10123055A1 (de) 2001-05-11 2003-03-20 Gruenenthal Gmbh Screeningverfahren mit PIM1-Kinase oder PIM3-Kinase
DE10226702A1 (de) 2002-06-14 2004-09-09 Grünenthal GmbH Antisense Oligonukleotide gegen PIM1
WO2006078228A1 (fr) 2002-09-16 2006-07-27 Plexxikon, Inc. Procedes de conception d'echafaudages moleculaires et de ligands
US20040142864A1 (en) 2002-09-16 2004-07-22 Plexxikon, Inc. Crystal structure of PIM-1 kinase
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
WO2004090106A2 (fr) 2003-04-04 2004-10-21 Vertex Pharmaceuticals Incorporated Structures cristallines de complexes proteiques humains de la pim-1 kinase et poches de liaison de ces structures, et leurs utilisations dans la conception de medicaments
WO2005028624A2 (fr) 2003-09-15 2005-03-31 Plexxikon, Inc. Echafaudages moleculaires pour le developpement de ligands des proteines kinases
WO2005033310A1 (fr) 2003-10-01 2005-04-14 Grünenthal GmbH Composes dsrna pim-1-specifiques
WO2006006569A1 (fr) 2004-07-12 2006-01-19 Nihon Nohyaku Co., Ltd. Dérivé de phénylpyridine ou sel de celui-ci, herbicide contenant celui-ci comme ingrédient actif et procédé d'utilisation de celui-ci
AU2005321966B2 (en) 2004-12-28 2011-11-17 Atnx Spv, Llc Compositions and methods of treating cell proliferation disorders
WO2007002433A1 (fr) 2005-06-22 2007-01-04 Plexxikon, Inc. Derives de pyrrolo [2, 3-b] pyridine utilises comme inhibiteurs de proteines kinases
WO2007011760A2 (fr) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibiteurs de la kinesine mitotique
EP1749822B1 (fr) * 2005-08-05 2008-10-15 Hybrigenics S.A. Nouvelles inhibiteurs de cysteine protease et leur utilisation therapeutique
ATE533770T1 (de) 2005-10-06 2011-12-15 Schering Corp Pyrazolopyrimidine als proteinkinaseinhibitoren
AU2006302174B2 (en) 2005-10-06 2013-06-20 Exelixis, Inc. Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3
EP1948663B1 (fr) 2005-10-21 2011-09-14 Exelixis, Inc. Pyrazolopyrimidines en tant que modulateurs de caseine kinase ii (ck2)
WO2007052843A1 (fr) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited Compose amide heterocyclique et son utilisation
WO2007084857A2 (fr) 2006-01-13 2007-07-26 President And Fellows Of Harvard College Procédés et compositions de traitement de troubles prolifératifs cellulaires
US20090253156A1 (en) 2006-05-05 2009-10-08 Perkinelmer Las, Inc. Mass spectrometry methods for multiplexed quantification of protein kinases and phosphatases
JP5564251B2 (ja) 2006-06-29 2014-07-30 キネックス ファーマシューティカルズ， エルエルシー キナーゼカスケードを調節するためのビアリール組成物および方法
ES2500165T3 (es) 2006-06-29 2014-09-30 Kinex Pharmaceuticals, Llc Composiciones de biarilo y métodos para modular una cascada de quinasas
US8318723B2 (en) 2006-08-16 2012-11-27 Boehringer Ingelheim International Gmbh Pyrazine compounds, their use and methods of preparation
WO2008045252A2 (fr) 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Peptides modifies de liaison aux integrines
AU2007314305B2 (en) 2006-10-31 2013-01-24 Merck Sharp & Dohme Corp. 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
CA2667487C (fr) 2006-11-06 2017-04-04 Supergen, Inc. Derives d'imidazo[1,2-b]pyridazine et de pyrazolo[1,5-a]pyrimidine et utilisation de ceux-ci comme inhibiteurs de proteines kinases
WO2008082839A2 (fr) 2006-12-29 2008-07-10 Abbott Laboratories Inhibiteurs de la pim kinase comme agents chimiothérapeutiques destinés à lutter contre le cancer
WO2008082840A1 (fr) 2006-12-29 2008-07-10 Abbott Laboratories Inhibiteurs de la pim kinase utilisés comme agents chimiothérapeutiques contre le cancer
EA019951B1 (ru) 2007-03-01 2014-07-30 Новартис Аг Ингибиторы киназы pim и способы их применения
CA2682231A1 (fr) 2007-03-28 2008-10-09 Array Biopharma Inc. Composes imidazo[1,2-a]pyridine en tant qu'inhibiteurs de la tyrosine kinase recepteur
UA101611C2 (ru) 2007-04-03 2013-04-25 Аррей Байофарма Инк. СОЕДИНЕНИЯ ИМИДАЗО[1,2-а]ПИРИДИНА КАК ИНГИБИТОРЫ ТИРОЗИНКИНАЗЫ РЕЦЕПТОРОВ
US8324231B2 (en) 2007-04-25 2012-12-04 Exelixis, Inc. Pyrimidinones as casein kinase II (CK2) modulators
CA2685106A1 (fr) 2007-04-25 2008-11-06 Exelixis, Inc. 6-phenylpyrimidinones comme modulateurs pim
CN101801958B (zh) 2007-07-19 2014-01-29 默沙东公司 作为蛋白质激酶抑制剂的杂环酰胺化合物
KR20100042287A (ko) 2007-07-31 2010-04-23 쉐링 코포레이션 항암요법으로서의 항-유사분열제 및 아우로라 키나제 억제제 조합물
AR067813A1 (es) * 2007-08-06 2009-10-21 Janssen Pharmaceutica Nv Fenilendiaminas sustituidas como inhibidores de l ainteraccion entre mdm2 y p53
WO2009064486A2 (fr) 2007-11-15 2009-05-22 Musc Foundation For Research Development Inhibiteurs de protéines kinases pim, compositions et procédés pour traiter le cancer
JP2011503207A (ja) 2007-11-16 2011-01-27 サン ディエゴ ステート ユニバーシティ リサーチ ファウンデーション 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法
CN102036561A (zh) 2008-02-29 2011-04-27 赛林药物股份有限公司 蛋白激酶调节剂
AR070531A1 (es) 2008-03-03 2010-04-14 Novartis Ag Inhibidores de cinasa pim y metodos para su uso
US8168794B2 (en) 2008-03-03 2012-05-01 Novartis Ag Pim kinase inhibitors and methods of their use
US20110294789A1 (en) 2008-05-12 2011-12-01 Amnestix, Inc. Compounds for rho kinase inhibition and for improving learning and memory
AU2009267048A1 (en) 2008-06-30 2010-01-07 Cylene Pharmaceuticals, Inc. Oxindole compounds
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
FR2933409B1 (fr) 2008-07-03 2010-08-27 Centre Nat Rech Scient NOUVEAUX PYRROLO °2,3-a! CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM
US8557809B2 (en) 2008-08-19 2013-10-15 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物
BRPI0918268B1 (pt) 2008-09-02 2021-08-03 Novartis Ag Derivados de picolinamida, seu uso, e composição farmacêutica
US8759338B2 (en) 2008-09-02 2014-06-24 Novartis Ag Heterocyclic kinase inhibitors
MX2011002367A (es) 2008-09-02 2011-04-04 Novartis Ag Inhibidores de cinasa biciclicos.
SG10201914059WA (en) 2008-10-22 2020-03-30 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
GB0821307D0 (en) 2008-11-21 2008-12-31 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
TW201035100A (en) 2008-12-19 2010-10-01 Cephalon Inc Pyrrolotriazines as ALK and JAK2 inhibitors
CN102459270B (zh) * 2009-04-20 2015-04-29 奥斯拜客斯制药有限公司 Janus激酶3的哌啶抑制剂
US20120128631A1 (en) 2009-05-19 2012-05-24 San Diego State University (SDSU) Foundation, dba San Diego State University (SDSU) Research Compositions and methods for kinase-mediated cytoprotection and enhanced cellular engraftment and persistence
NZ596571A (en) 2009-05-20 2013-03-28 Cylene Pharmaceuticals Inc Pyrazolopyrimidines and related heterocycles as kinase inhibitors
WO2010135571A1 (fr) 2009-05-20 2010-11-25 Cylene Pharmaceuticals, Inc. Modulateurs inédits des protéines kinases
TW201100429A (en) 2009-05-22 2011-01-01 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US20100331315A1 (en) 2009-06-18 2010-12-30 Mustapha Haddach Rhodanines and related heterocycles as kinase inhibitors
HRP20140754T2 (hr) 2009-06-29 2015-07-17 Incyte Corporation Pirimidinoni kao inhibitori pi3k
IN2012DN02596A (fr) 2009-08-26 2015-08-28 Cylene Pharmaceuticals Inc
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US8435976B2 (en) 2009-09-08 2013-05-07 F. Hoffmann-La Roche 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
EP2475659B1 (fr) 2009-09-08 2015-10-28 F.Hoffmann-La Roche Ag Composés de pyridin-3-yl-carboxamide 4-substitué et procédés d'utilisation
CN102625803A (zh) 2009-09-11 2012-08-01 赛林药物股份有限公司 药学上有用的杂环-取代的内酰胺
AU2010295622A1 (en) 2009-09-16 2012-05-10 Cylene Pharmaceuticals, Inc. Tricyclic compounds and pharmaceutical uses thereof
BR112012005970A2 (pt) 2009-09-16 2015-09-08 Cylene Pharmaceuticals Inc moduladores tricíclicos de proteína quinase
US8404677B2 (en) 2009-10-29 2013-03-26 Genosco Kinase inhibitors
EP2332917B1 (fr) 2009-11-11 2012-08-01 Sygnis Bioscience GmbH & Co. KG Composés pour l'inhibition de kinase PIM et pour le traitement des tumeurs
CN102712601A (zh) 2009-11-12 2012-10-03 赛尔维他股份公司 化合物、其制备方法、药物组合物、化合物的用途、用于调节或调控丝氨酸/苏氨酸激酶的方法以及丝氨酸/苏氨酸激酶调节剂
WO2011060295A1 (fr) 2009-11-13 2011-05-19 Genosco Inhibiteurs de kinases
US8853235B2 (en) 2009-11-23 2014-10-07 Senhwa Biosciences, Inc. Polymorphs and salts of a kinase inhibitor
JP5802676B2 (ja) 2009-12-04 2015-10-28 センワ バイオサイエンシズ インコーポレイテッド Ｃｋ２阻害剤としてのピラゾロピリミジンおよび関連複素環化合物
AR079529A1 (es) 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
WO2011075613A1 (fr) 2009-12-18 2011-06-23 Sanofi Dérivés d'azaindole, leur préparation et leur application thérapeutique
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
CN102884062B (zh) 2009-12-23 2016-08-03 嘉世高制药公司 氨基嘧啶激酶抑制剂
GB201002861D0 (en) 2010-02-19 2010-04-07 Cxr Biosciences Ltd Compositions
PH12015502575A1 (en) 2010-03-10 2017-04-24 Incyte Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors
CA2794801C (fr) 2010-04-07 2019-01-15 F. Hoffmann-La Roche Ag Composes pyrazol-4-yl-heterocyclyle-carboxamide et leurs procedes d'utilisation
WO2011130342A1 (fr) 2010-04-14 2011-10-20 Incyte Corporation Dérivés condensés en tant qu'inhibiteurs de ρi3κδ
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
WO2012004217A1 (fr) 2010-07-06 2012-01-12 Novartis Ag Composés éthers cycliques utiles comme inhibiteurs de kinase
KR101995013B1 (ko) 2010-07-13 2019-07-02 에프. 호프만-라 로슈 아게 Irak4 조절제로서 피라졸로[1,5a]피리미딘 및 티에노[3,2b]피리미딘 유도체
PT2598483T (pt) 2010-07-29 2020-10-12 Rigel Pharmaceuticals Inc Compostos heterocíclicos de ativação de ampk e métodos de utilização dos mesmos
US8227773B2 (en) 2010-07-29 2012-07-24 Axcelis Technologies, Inc. Versatile beam glitch detection system
US8802099B2 (en) 2010-11-10 2014-08-12 National Jewish Health Methods to treat allergic conditions
WO2012065297A1 (fr) 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-aryl-6-aryl-[1,2,4]triazolo[4,3-a]pyridines en tant qu'inhibiteurs de la prolifération cellulaire et leur utilisation
CN103415515B (zh) 2010-11-19 2015-08-26 因塞特公司 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物
CA2818545C (fr) 2010-11-19 2019-04-16 Incyte Corporation Pyrrolopyridines et pyrrolopyrimidines a substitution heterocyclique utilisees en tant qu'inhibiteurs des jak
AU2011338389A1 (en) 2010-12-09 2013-06-13 Amgen Inc. Bicyclic compounds as Pim inhibitors
CA2812223C (fr) 2010-12-17 2019-03-12 Nerviano Medical Sciences S.R.L. Derives de pyrazolo-quinazoline substitues a titre d'inhibiteurs de kinases
WO2012087881A1 (fr) 2010-12-20 2012-06-28 Incyte Corporation N-(1-(phényl substitué)éthyl)-9h-purin-6-amines en tant qu'inhibiteurs de pi3k
WO2012101029A1 (fr) 2011-01-26 2012-08-02 Nerviano Medical Sciences S.R.L. Dérivés tricycliques, leur procédé de préparation et leur utilisation à titre d'inhibiteurs de kinases
EP2668190B1 (fr) 2011-01-26 2016-08-17 Nerviano Medical Sciences S.r.l. Dérivés pyrrolo tricycliques, leur procédé de préparation et leur utilisation à titre d'inhibiteurs de kinases
JP6039585B2 (ja) 2011-02-25 2016-12-07 アレイ バイオファーマ、インコーポレイテッド Ｐｉｍキナーゼ阻害剤としてのトリアゾロピリジン化合物
UY33930A (es) 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
EP2681197A1 (fr) 2011-03-04 2014-01-08 Novartis AG Composés de cyclohexyle tétrasubstitués à titre d'inhibiteurs de kinases
WO2012125629A1 (fr) 2011-03-14 2012-09-20 Incyte Corporation Dérivés diamino-pyrimidines et diamino-pyridines substituées en tant qu'inhibiteurs de pi3k
CA2830780A1 (fr) 2011-03-22 2012-09-27 Amgen Inc. Composes d'azole utilises en tant qu'inhibiteurs des pim
WO2012135009A1 (fr) 2011-03-25 2012-10-04 Incyte Corporation Dérivés de pyrimidine-4,6-diamine en tant qu'inhibiteurs de pi3k
AP2013007159A0 (en) 2011-04-05 2013-10-31 Pfizer Ltd Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of tropomyosin-related kinase
US9284298B2 (en) 2011-04-11 2016-03-15 Nerviano Medical Sciences S.R.L. Pyrazolyl-pyrimidine derivatives as kinase inhibitors
AU2012245344B2 (en) 2011-04-22 2017-11-09 Jasco Pharmaceuticals, LLC Aminopyrimidine kinase inhibitors
GB201107176D0 (en) 2011-04-28 2011-06-15 Cxr Biosciences Ltd Pyrrolnitrin derivatives
GB201107197D0 (en) 2011-04-28 2011-06-15 Cxr Biosciences Ltd Compounds
CA2834166A1 (fr) 2011-04-29 2012-11-01 Amgen Inc. Composes pyridazines bicycliques en tant qu'inhibiteurs de pim
CN103687858B (zh) 2011-05-17 2017-11-21 拜耳知识产权有限责任公司 作为mknk1激酶抑制剂的氨基取代的咪唑并哒嗪
CA2872979C (fr) 2011-05-19 2020-02-18 Joaquin Pastor Fernandez Composes macrocycliques en tant qu'inhibiteurs de proteine kinases
KR20140048891A (ko) 2011-05-27 2014-04-24 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 치환된 2-벤질리덴-2H-벤조[b][1,4]티아진-3(4H)-온, 이의 유도체, 및 이의 치료적 용도
US9730929B2 (en) 2011-06-01 2017-08-15 Bayer Intellectual Property Gmbh Substituted aminoimidazopyridazines
WO2012170827A2 (fr) 2011-06-08 2012-12-13 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines et hétérocycles associés comme inhibiteurs de ck2
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
HK1197063A1 (en) 2011-06-22 2015-01-02 拜耳知识产权有限责任公司 Heterocyclyl aminoimidazopyridazines
US9416132B2 (en) 2011-07-21 2016-08-16 Tolero Pharmaceuticals, Inc. Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
CN102924446B (zh) 2011-08-11 2015-08-26 上海吉铠医药科技有限公司 Pim激酶抑制剂及其制备方法与在制药中的应用
CN103874700B (zh) 2011-08-12 2018-03-30 霍夫曼-拉罗奇有限公司 吡唑并[3,4‑c]吡啶化合物和使用方法
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
LT3196202T (lt) * 2011-09-02 2019-07-10 Incyte Holdings Corporation Heterociklilaminai, kaip pi3k slopikliai
JP5843524B2 (ja) 2011-09-02 2016-01-13 キヤノン株式会社 有機無機複合組成物、有機無機複合材料、光学素子および積層型回折光学素子
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US8735528B1 (en) * 2011-09-20 2014-05-27 The United States Of America As Represented By The Secretary Of The Air Force Two-photon absorbing cross-linked polyurethanes containing diphenylamino-dialkylfluorene-1,3,5-triazine units
CN103814029B (zh) 2011-09-23 2016-10-12 拜耳知识产权有限责任公司 取代的咪唑并哒嗪
KR20140074964A (ko) 2011-09-27 2014-06-18 에프. 호프만-라 로슈 아게 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 사용 방법
EP2788350B1 (fr) 2011-10-07 2017-12-06 Nerviano Medical Sciences S.r.l. Dérivés 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2h)-one substitué par 4-alkyle en tant qu'inhibiteurs de kinases
ES2639064T3 (es) 2011-10-07 2017-10-25 Nerviano Medical Sciences S.R.L. Derivados de 3,4-dihidropirrolo[1,2-a]pirazin-1(2h)-ona sustituidos como inhibidores de cinasa
CN104011046B (zh) 2011-11-04 2017-05-03 嘉世高制药公司 氨基嘧啶激酶抑制剂
US9394297B2 (en) 2012-02-28 2016-07-19 Amgen Inc. Amides as pim inhibitors
WO2013134079A1 (fr) 2012-03-05 2013-09-12 Amgen Inc. Composés d'oxazolidinone et leurs dérivés
US9777004B2 (en) 2012-03-29 2017-10-03 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
CN104321326B (zh) 2012-04-04 2017-05-31 拜耳医药股份有限公司 氨基取代的咪唑并哒嗪
TWI572605B (zh) 2012-04-26 2017-03-01 必治妥美雅史谷比公司 血小板聚集之抑制劑
JP6042529B2 (ja) 2012-04-27 2016-12-14 ノバルティス アーゲー 環式橋頭エーテルｄｇａｔ１阻害剤
RS58058B1 (sr) 2012-05-09 2019-02-28 Biogen Ma Inc Modulatori nukleusnog transporta i njihove upotrebe
CN104302638B (zh) 2012-05-15 2016-08-24 诺华股份有限公司 用于抑制abl1、abl2和bcr-abl1的活性的苯甲酰胺衍生物
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
WO2013175388A1 (fr) 2012-05-21 2013-11-28 Novartis Ag Nouveaux n-pyridinylamides substitués par un cycle à titre d'inhibiteurs de kinase
BR112014029115A8 (pt) 2012-05-22 2018-04-03 Idenix Pharmaceuticals Inc Composto, composição farmacêutica, e, uso de um composto ou composição
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
CN104428299B (zh) 2012-06-27 2018-05-11 霍夫曼-拉罗奇有限公司 5-氮杂吲唑化合物及其使用方法
TW201408652A (zh) 2012-07-11 2014-03-01 Hoffmann La Roche 作爲ＲＯＲｃ調節劑之芳基磺內醯胺衍生物
TW201414737A (zh) 2012-07-13 2014-04-16 必治妥美雅史谷比公司 作爲激酶抑制劑之咪唑并三□甲腈
WO2014022752A1 (fr) 2012-08-03 2014-02-06 Amgen Inc. Macrocycles en tant qu'inhibiteurs de pim
WO2014033630A1 (fr) 2012-08-31 2014-03-06 Novartis Ag Nouveaux carboxamides d'aminothiazole en tant qu'inhibiteurs de kinase
WO2014033631A1 (fr) 2012-08-31 2014-03-06 Novartis Ag N- (3-pyridyl)-biarylamides en tant qu'inhibiteurs de kinase
CN103664878A (zh) 2012-09-12 2014-03-26 山东亨利医药科技有限责任公司 杂芳环及其衍生物类酪氨酸激酶抑制剂
BR112015005743A2 (pt) 2012-09-14 2017-07-04 Abbvie Deutschland derivados tricíclicos de quinoxalina e quinolina
SI2900657T1 (sl) 2012-09-26 2020-07-31 F. Hoffmann-La Roche Ag Ciklični eter pirazol-4-il-heterociklil-karboksamidne spojine in načini uporabe
WO2014053568A1 (fr) 2012-10-02 2014-04-10 Sanofi Dérivés d'indolyldihydroimidazopyrimidinone, leur préparation et utilisation thérapeutique
BR112015008325B1 (pt) 2012-10-16 2022-01-25 Janssen Sciences Ireland Uc Compostos antivirais contra o rsv, seu uso e composição farmacêutica que os compreende
CA2888816A1 (fr) 2012-11-01 2014-05-08 Incyte Corporation Derives de thiophene condenses tricycliques a titre d'inhibiteurs de jak
EP2920176B1 (fr) 2012-11-19 2017-09-13 Bayer Pharma Aktiengesellschaft Aminoimidazopyridazine en tant qu`inhibiteurs de mknk1 kinase
WO2014079011A1 (fr) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Composés hétérocycliques pour inhiber la glutaminase et procédés d'utilisation de ceux-ci
PT4190786T (pt) 2012-12-07 2025-05-29 Vertex Pharma Compostos úteis como inibidores da quinase atr
KR102075885B1 (ko) 2012-12-18 2020-02-11 버텍스 파마슈티칼스 인코포레이티드 세균 감염 치료용 만노스 유도체
US20150336960A1 (en) 2012-12-19 2015-11-26 Novartis Ag Aryl-substituted fused bicyclic pyridazine compounds
CN104968656B (zh) 2012-12-19 2017-08-11 诺华股份有限公司 自分泌运动因子抑制剂
DK3067358T3 (da) 2012-12-21 2019-11-04 Gilead Sciences Inc Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse
EP3498701B1 (fr) 2012-12-21 2023-02-22 Epizyme Inc Inhibiteurs de prmt5 et utilisations associées
FR3000569B1 (fr) 2013-01-03 2015-02-13 Peugeot Citroen Automobiles Sa Dispositif d'eclairage a ecran a bord(s) lumineux
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
LT2945939T (lt) 2013-01-15 2020-07-27 Incyte Holdings Corporation Triazolkarboksamidai ir piridinkarboksamido junginiai, naudotini kaip pim kinazės inhibitoriai
TWI657090B (zh) 2013-03-01 2019-04-21 英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途
BR112015021458B1 (pt) 2013-03-06 2022-06-07 Incyte Holdings Corporation "processos e intermediários para preparar {1-{1-[3-flúor2-(trifluormetil)isonicotinoil] piperidin-4-il}-3-[4-(7hpirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrila, útil no tratamento de doenças relacionadas com a atividade de janus quinases
JO3383B1 (ar) 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US20140275108A1 (en) 2013-03-15 2014-09-18 Galderma Research & Development Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
RU2680100C9 (ru) 2013-03-15 2019-04-18 Плексксикон Инк. Гетероциклические соединения и их применения
CN109134440A (zh) 2013-03-15 2019-01-04 美国陶氏益农公司 除草化合物及其作为除草剂的用途
EA029309B1 (ru) 2013-03-15 2018-03-30 Идорсиа Фармасьютиклз Лтд Производные пиридин-4-ила в качестве агонистов s1p/edg1
US20160052926A1 (en) 2013-03-15 2016-02-25 Hutchison Medipharma Limited Novel pyrimidine and pyridine compounds and usage thereof
TWI689490B (zh) 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
TWI719464B (zh) 2013-03-15 2021-02-21 美商英塞特控股公司 作為bet蛋白抑制劑之三環雜環
CN105051015B (zh) 2013-03-15 2018-09-25 日本烟草产业株式会社 吡唑-酰胺化合物和其医药用途
TWI742541B (zh) 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
JO3279B1 (ar) 2013-03-15 2018-09-16 Respivert Ltd مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز
PE20151900A1 (es) 2013-03-15 2016-01-20 Global Blood Therapeutics Inc Compuestos y sus usos para modular la hemoglobina
UY35421A (es) 2013-03-15 2014-10-31 Nihon Nohyaku Co Ltd Compuesto heterocíclico condensado o su sal, insecticida agrícola u hortícola que comprende el comp uesto y método de uso del insecticida
AR095443A1 (es) 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii Heterociclos condensados con acción sobre atr
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
WO2015021153A1 (fr) 2013-08-07 2015-02-12 Incyte Corporation Formes galéniques à libération prolongée pour un inhibiteur jak1
EP3036238A1 (fr) 2013-08-23 2016-06-29 Incyte Corporation Composés de furo- et thiéno-pyridinecarboxamide utiles en tant qu'inhibiteurs de kinases pim
SI3110409T1 (sl) 2014-02-28 2018-11-30 Incyte Corporation Inhibitorji JAK1 za zdravljenje mielodisplastičnih sindromov
NZ763326A (en) 2014-04-08 2023-04-28 Incyte Holdings Corp Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
CR20160553A (es) 2014-04-30 2017-04-25 Incyte Corp Procesos para preparar un inhibidor de jak1 y nuevas formas de este
WO2015184305A1 (fr) 2014-05-30 2015-12-03 Incyte Corporation Traitement de la leucémie neutrophile chronique (cnl) et de la leucémie myéloïde chronique atypique (acml) par des inhibiteurs de jak1
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (fr) 2015-10-02 2017-04-06 Incyte Corporation Composés hétérocycliques utiles en tant qu'inhibiteurs de la kinase pim

Also Published As

Publication number Publication date
AU2016320892B2 (en) 2021-03-11
JP6943844B2 (ja) 2021-10-06
BR112018004596A2 (pt) 2018-09-25
UA124877C2 (uk) 2021-12-08
CN108349938A (zh) 2018-07-31
AU2016320892A8 (en) 2021-03-11
AU2021203351A1 (en) 2021-06-24
US12043614B2 (en) 2024-07-23
MY196185A (en) 2023-03-21
ES2914686T3 (es) 2022-06-15
US11066387B2 (en) 2021-07-20
KR102720267B1 (ko) 2024-10-22
NZ741260A (en) 2024-11-29
TW201722927A (zh) 2017-07-01
CN114380798A (zh) 2022-04-22
CL2018000611A1 (es) 2018-07-20
IL257897A (en) 2018-06-03
EP3347351B1 (fr) 2022-03-30
ZA201802267B (en) 2022-10-26
IL257897B2 (en) 2024-02-01
JP2018532713A (ja) 2018-11-08
AR105967A1 (es) 2017-11-29
TWI734699B (zh) 2021-08-01
US9862705B2 (en) 2018-01-09
KR20180067531A (ko) 2018-06-20
MX388988B (es) 2025-03-20
US20210155605A1 (en) 2021-05-27
MX2021015824A (es) 2022-04-01
IL257897B1 (en) 2023-10-01
SG10201912287XA (en) 2020-02-27
EP3347351A1 (fr) 2018-07-18
US20190270725A1 (en) 2019-09-05
US20180170907A1 (en) 2018-06-21
ECSP18026386A (es) 2018-07-31
PH12018500511A1 (en) 2018-09-03
CL2019002078A1 (es) 2019-12-27
CA2997768A1 (fr) 2017-03-16
CL2019002079A1 (es) 2019-10-18
IL306054A (en) 2023-11-01
US20170121310A1 (en) 2017-05-04
US10336728B2 (en) 2019-07-02
HK1256806A1 (en) 2019-10-04
CO2018003739A2 (es) 2018-08-31
MX2018002885A (es) 2018-09-18
MY187993A (en) 2021-11-08
PE20181337A1 (es) 2018-08-21
AU2021203351B2 (en) 2022-04-21
US11505540B2 (en) 2022-11-22
WO2017044730A1 (fr) 2017-03-16
CN108349938B (zh) 2024-11-29
AU2016320892C1 (en) 2022-08-11
US20230111912A1 (en) 2023-04-13
US20250019366A1 (en) 2025-01-16
CA2997768C (fr) 2024-06-11
EA201890663A1 (ru) 2018-10-31
AU2016320892A1 (en) 2018-04-26
CN114380798B (zh) 2024-10-15

Similar Documents

Publication Publication Date Title
CY2024003I2 (el) Ενωσεις χρησιμες ως αναστολεις κινασης
MA42606A (fr) Sels d'un inhibiteur de lsd1
MA42780A (fr) Sels d'un inhibiteur de la kinase pim
IL269812A (en) Ferroportin-inhibitor salts
IL259719A (en) Tank-binding kinase inhibitor compounds
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
EP3964503C0 (fr) Une forme cristalline d'un inhibiteur de magl
EP3152210C0 (fr) Composés inhibiteurs de kinases se liant à tank
HUE050842T2 (hu) Janus-kináz inhibitor
ME03334B (fr) Composés hétéroaryle d'inhibition de la kinase
MA41350A (fr) Synthèse d'un inhibiteur de la tyrosine kinase de bruton
EP3347018A4 (fr) Inhibiteurs de kinases cycline-dépendantes
HRP20190324T1 (hr) Inhibitor aurora a kinaze
DK3668955T3 (da) Korrosionsinhibitor
MA41827A (fr) Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
EP3562487A4 (fr) Composés inhibiteurs des métalloenzymes
EP3556758A4 (fr) Inhibiteur de cdk4/6
IL255625B (en) Salts and prodrugs of 1-methyl-d-tryptophan
EP3415524A4 (fr) INHIBITEUR D'EXPRESSION DE L'a-SYNUCLÉINE
EP3365477A4 (fr) Inhibition de la corrosion
IL267393B1 (en) Crystal forms of a Janus kinase inhibitor
EP2976339A4 (fr) Cyanoéthylpyrazolopyridones à substitution géminale utilisées comme inhibiteurs de la janus kinase
EP3394070A4 (fr) Formes cristallines d'analogues de quinolone et leurs sels
MA44607A (fr) Inhibiteurs de kinase
HUE050890T2 (hu) Nilotinib sók szilárd halmazállapotú formái